Varian, a Siemens Healthineers company, today announced the European launch of IntelliBlate, its next-generation microwave ablation solution designed for the treatment of soft tissue tumors. Now CE-marked, IntelliBlate marks a significant advancement in making integrated, intuitive, and minimally invasive cancer treatment more accessible to clinicians and patients across Europe.
Engineered to offer enhanced precision, predictability, and control, IntelliBlate plays a central role in Varian’s vision of a fully integrated microwave ablation ecosystem. It seamlessly connects with Siemens Healthineers’ imaging and software technologies, including the myAblation Guide for procedural planning and confirmation, the myNeedle Laser system for CT-guided needle placement, and ultrasound for assessment and monitoring. This end-to-end integration enables clinicians to plan, guide, treat, monitor, and confirm ablation therapy within a single workflow, simplifying procedures and improving confidence in targeting.
Designed to meet diverse clinical needs, IntelliBlate produces large, controlled spherical ablation zones that enable consistent and predictable treatment outcomes. A key feature, the Ximitry probe, includes embedded thermocouples for real-time temperature monitoring inside and outside the ablation zone, allowing clinicians to respond dynamically during procedures and make well-informed decisions.
The system combines two generators in one compact, portable unit. With an intuitive interface, quick setup, and pre-programmed ablation zone settings, IntelliBlate helps reduce procedural complexity and improve treatment efficiency.
Following FDA clearance in 2024, IntelliBlate makes its European debut at a time when clinical evidence supporting thermal ablation is stronger than ever. The COLLISION trial, a large international phase 3 study published in The Lancet Oncology, demonstrated that thermal ablation can be as effective as surgical resection for treating small colorectal liver metastases (CRLM). The study also showed that ablation leads to fewer complications, similar overall survival rates, and shorter hospital stays.
Commenting on the findings, Franck Facchini, President of Interventional Solutions at Varian, said, “The results of the COLLISION trial mark a milestone in how we think about ablation. We now have compelling evidence that thermal ablation should be considered a first-line treatment option, not just a fallback for patients who can’t undergo surgery. IntelliBlate was built with this shift in mind—merging precision, imaging, and intelligent software into a system tailored for modern cancer care.”
IntelliBlate will be introduced to the European medical community in September at CIRSE 2025, the leading European Congress for interventional radiology. Varian and Siemens Healthineers will provide hands-on demonstrations and educational sessions to support clinician training, share best practices, and promote early adoption.
Representing a more targeted and less invasive approach to cancer care, IntelliBlate expands the therapeutic options available to clinicians and gives patients renewed hope. It embodies Varian’s commitment to innovation in interventional oncology and reflects the company’s shared mission with Siemens Healthineers to create a smart, connected future in image-guided therapy—advancing toward a world without the fear of cancer.